

Anna Zielińska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7017964/publications.pdf>

Version: 2024-02-01

29
papers

967
citations

516215

16
h-index

525886

27
g-index

29
all docs

29
docs citations

29
times ranked

1202
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. <i>Pharmacological Research</i> , 2021, 172, 105840.	3.1	201
2	Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. <i>Journal of Gastroenterology</i> , 2014, 49, 24-45.	2.3	151
3	Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2016, 7, 459.	1.6	71
4	Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1137-1145.	0.9	61
5	Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 6016-6033.	5.4	52
6	Role of Transient Receptor Potential Channels in Intestinal Inflammation and Visceral Pain. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 419-427.	0.9	50
7	Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives. <i>Pharmacological Reports</i> , 2016, 68, 837-846.	1.5	43
8	Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. <i>International Journal of Colorectal Disease</i> , 2019, 34, 217-227.	1.0	39
9	Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. <i>Biochemical Pharmacology</i> , 2014, 92, 618-626.	2.0	28
10	Anti-Inflammatory and Antinociceptive Action of an Orally Available Nociceptin Receptor Agonist SCH 221510 in a Mouse Model of Inflammatory Bowel Diseases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 401-409.	1.3	28
11	Circadian rhythm abnormalities – Association with the course of inflammatory bowel disease. <i>Pharmacological Reports</i> , 2016, 68, 847-851.	1.5	28
12	Effect of 2,6-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6977-6981.	1.4	26
13	Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6966.	1.8	24
14	Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3204.	1.8	21
15	Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases. <i>Current Drug Targets</i> , 2013, 14, 1203-1209.	1.0	20
16	Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2014, 66, 741-750.	1.5	18
17	Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 275-286.	1.9	16
18	Supplementation of Bovine Colostrum in Inflammatory Bowel Disease: Benefits and Contraindications. <i>Advances in Nutrition</i> , 2021, 12, 533-545.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Chronic abdominal pain in irritable bowel syndrome – current and future therapies. Expert Review of Clinical Pharmacology, 2018, 11, 729-739.	1.3	13
20	The role of adipose tissue in the pathogenesis of Crohn’s disease. Pharmacological Reports, 2019, 71, 105-111.	1.5	13
21	Circadian rhythm abnormalities in patients with inflammatory bowel disease – association with adipokine profile. Scandinavian Journal of Gastroenterology, 2020, 55, 294-300.	0.6	10
22	Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy, 2020, 21, 73-84.	0.9	9
23	The association of bone turnover markers with pro- and anti-inflammatory adipokines in patients with gestational diabetes. Annals of Agricultural and Environmental Medicine, 2015, 22, 307-312.	0.5	9
24	Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients. Antioxidants, 2021, 10, 1237.	2.2	8
25	Morphometric analysis of mitochondria in lymphocytes of patients with exacerbations of chronic obstructive pulmonary disease – pilot study. International Journal of COPD, 2018, Volume 13, 2313-2318.	0.9	5
26	The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency. Pharmaceuticals, 2021, 14, 284.	1.7	3
27	The Anti-Inflammatory Effect of Acidic Mammalian Chitinase Inhibitor OAT-177 in DSS-Induced Mouse Model of Colitis. International Journal of Molecular Sciences, 2022, 23, 2159.	1.8	3
28	Pain in irritable bowel syndrome. , 2020, , 145-166.		1
29	The effects of melatonin, N-acetylserotonin, and 6-hydroxymelatonin on the ultrastructure of the pinealocytes of the Syrian hamster (Mesocricetus auratus). Endokrynologia Polska, 2006, 57, 2-6.	0.3	0